Aging is the primary risk factor for AD, with emerging evidence supporting the age‐dependent amyloid cascade hypothesis, which suggests that amyloid pathology precedes tauopathy.[53] To evaluate the translational potential of VUF6002 in advanced AD, we treated aged APP/PS1 (12 months old) and 3xTg‐AD (13 months old) mice with VUF6002 for 2 months (Figure2A). This evidence concerns the gene APP and amyloidosis.